New JCCP Guidance on Advertising POMs in Aesthetics

Prescription-only medicines cannot be advertised to the public in the UK, and botulinum toxin, the medicine behind the most common injectable treatment in aesthetics, is no exception. New guidance from the Joint Council for Cosmetic Practitioners restates that rule and closes several of the workarounds practitioners have relied on, from euphemisms like “wrinkle-relaxing injections” to altered brand spellings.

The confusion around this is understandable. Practitioners need to market their services to survive commercially, but the medicine at the centre of the most popular injectable treatment in the UK cannot legally be advertised to the public in any form. Understanding exactly where that line sits, and why it exists, matters for anyone running a clinic’s marketing.

What the New JCCP Guidance Changes for Clinics Advertising POMs

Why the JCCP Issued Updated Guidance Now

The JCCP Advertising and Promotion Policy sits alongside the JCCP’s registration requirements: taking the policy into account is a condition of being on the JCCP Practitioner Register. The guidance was refreshed in response to continued reports of non-compliant advertising across social media, particularly among newer practitioners who trained during a period when enforcement had eased and assumed the old workarounds still applied. The update does not introduce new law. It restates the existing legal position under the Human Medicines Regulations 2012 in more direct language, closing some of the interpretive gaps practitioners had been using.

What Counts as Advertising a POM

“Advertising” is defined broadly. It covers paid promotions, organic social posts, influencer content, price lists shared publicly, competition prizes, and even a clinic’s own reposts of someone else’s content. A post does not need to explicitly say “Botox” to count. If the wording, imagery or context makes the product obvious by inference, that counts as advertising under the rules, whether or not the brand name appears anywhere in the copy.

Why Botulinum Toxin Still Can’t Be Advertised to the Public

The Legal Basis: Human Medicines Regulations and the CAP Code

Botulinum toxin is classified as a prescription-only medicine, which places it under Part 14 of the Human Medicines Regulations 2012. Rule 12.12 of the CAP Code translates that law into advertising practice: prescription-only medicines or prescription-only medical treatments cannot be advertised to the public, full stop. The MHRA Blue Guide sets out the detail behind that rule, and Appendix 6 specifically addresses treatment service providers, which is the category most aesthetic clinics fall into.

The Public Health Reasoning Behind the Ban

The rule exists because prescribing decisions are meant to be driven by clinical need, not consumer demand generated by marketing. A prescriber assessing whether botulinum toxin is appropriate for a patient should be working from a clinical assessment, not responding to a customer who has already been primed by an advert to expect a specific product at a specific price. Allowing POM advertising would shift that decision-making dynamic, which is why the restriction applies regardless of who is administering the treatment or how qualified they are. A GMC-registered doctor is bound by exactly the same advertising rule as a newly qualified nurse prescriber.

What Clinics Can and Can’t Say When Promoting Injectable Treatments

Banned Words, Phrases and Substitutes

The rule is not limited to the word “Botox.” Direct references to any brand name (Bocouture, Dysport, Azzalure, Letybo) or to the class name “botulinum toxin” are prohibited, as are deliberately altered spellings such as “Beautox” where the intended reference is obvious. Indirect substitutes carry exactly the same risk. Phrases like “wrinkle-relaxing injections,” “anti-wrinkle injections” used alongside a price, or “tox” as shorthand have all been treated by the ASA as indirect promotion, which the CAP Code treats identically to a direct reference. Hashtags and imagery are included too: a photograph of a needle near a forehead, paired with a price, can be enough to trigger a breach even without a single word naming the product.

What Is Still Permitted

Clinics can promote the consultation itself. Language such as “book a consultation to discuss treatment for lines and wrinkles” is generally acceptable, because it advertises the professional service rather than the medicine. A clinic can also list “Botox (3 areas)” alongside a price on a static price list, provided nothing further is added, such as claims about what the treatment does, and the price list is not shared or linked on social media. Advertising aimed exclusively at other registered healthcare professionals, rather than the public, sits outside these restrictions entirely, which is why trade publications and closed practitioner groups can discuss POMs in ways a public-facing Instagram account cannot.

What Happens When a Clinic Gets Advertising Wrong

Enforcement Routes: ASA, MHRA and Professional Regulators

The ASA enforcement notice on advertising Botox and other botulinum toxin injections set out the framework still used for compliance action today, and non-compliance can lead to a request to remove content, referral to the MHRA, or referral to the practitioner’s professional regulatory body. For a registered nurse or doctor, that last route can affect fitness-to-practise standing, which carries considerably more weight than a removed social media post.

A Recent Ruling Practitioners Should Know About

A 2024 ASA ruling against Therapie Clinic UK, prompted by complaints from the JCCP and Laser Clinics UK, found that a Facebook advert promoting “Cosmetic Injections” indirectly promoted Botox despite never naming it, because the surrounding claims and imagery made the product obvious. The full ASA ruling on the Therapie Clinic advert is a useful case study for any clinic marketer trying to judge where the line sits, since it shows the ASA reading intent and context rather than searching for a single banned word.

Building Compliance and Patient Safety Into Everyday Practice

Advertising restrictions push the real conversation about risk, dosage and expected results into the consultation room, which makes that consultation the single most important safety touchpoint a clinic has. It also means the clinic’s own internal systems need to carry weight that a public-facing advert no longer can. Consent processes, aftercare instructions and a clear plan for handling adverse reactions all matter more when a patient has arrived through a vague “book a consultation” advert rather than detailed marketing that already set expectations.

This is where having fast access to expert clinical advice becomes part of a clinic’s risk management, not just its patient care. Complications Consultant gives practitioners a direct line to specialist advice when a patient presents with an unexpected reaction, which matters most in the early hours after treatment when quick, correct triage affects outcomes. Clinics that pair careful, compliant advertising with a reliable route to complications support are better placed both clinically and reputationally, since a well-handled complication rarely becomes a regulatory or ASA issue in the first place.

Practices reviewing their adverse event processes alongside their advertising should also look at how they record and report reactions. The Faces Consent article on Yellow Card reporting for aesthetic practitioners covers the practical side of that reporting duty, and clinics working through recent safety alerts may find the piece on the MHRA’s new botulism warning useful for updating consent documentation to reflect current risk information.

Is Your Clinic’s Advertising CAP Code Compliant? And Who Do You Call When a Complication Hits?

Take a moment this week to review your clinic’s advertising against the current CAP Code position, and make sure you have a fast, reliable route to expert advice if a complication arises. Get set up with Complications Consultant, so you’re never guessing when a patient needs urgent, specialist input.

FAQs